NCT02652793

Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Judit Pich · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A 48-week, open label, non comparative prospective trial in stable chronic human immunodeficiency virus-infected patients having achieved complete virological suppression for more than 24 weeks (human immunodeficiency virus-1 RNA \<50 c/ml) switching from an antiretroviral regimen containing tenofovir and lamivudine or emtricitabine and boosted protease inhibitor to boosted atazanavir and lamivudine Study visits will take place at screening, baseline, weeks 4, 12, 24, and 48.

Conditions

• Human Immunodeficiency Virus

Interventions

Type	Name	Description
DRUG	Boosted atazanavir	Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly
DRUG	Lamivudine	Lamivudine 300 mg once dailly

Timeline

• Start date: 2015-11-01
• Primary completion: 2018-11-01
• Completion: 2018-11-01
• First posted: 2016-01-12
• Last updated: 2025-07-02
• Results posted: 2025-07-02

Locations

1 site across 1 country: Spain